Health
New Alzheimer’s treatment accelerates removal of plaque from the brain in clinical trials
A new Alzheimer’s therapy has shown potential in the first human trials.
Researchers at the West Virginia University Rockefeller Neuroscience Institute (RNI) found that by pairing focused ultrasound in combination with antibody therapies, they were able to accelerate the removal of amyloid-beta plaques from the brains of patients with Alzheimer’s disease.
The study findings were published in The New England Journal of Medicine on Jan. 11.
FASTING COULD REDUCE SIGNS OF ALZHEIMER’S DISEASE, STUDIES SUGGEST: ‘PROFOUND EFFECTS’
An abnormal buildup of amyloid-beta proteins is one of the hallmarks of Alzheimer’s, as these proteins clump together to form plaques that interfere with neurons in the brain.
Anti-amyloid-beta monoclonal antibody treatments, such as aducanumab and lecanemab, have proven to be effective in clearing these plaques and slowing disease progression.
An Alzheimer’s patient undergoes focused ultrasound treatment with the WVU RNI team. (Rockefeller Neuroscience Institute (RNI) at West Virginia University (WVU))
But until now the drugs have been limited by the blood-brain barrier (BBB), which is designed to keep harmful substances from reaching the brain, according to a press release from RNI.
“A study like this is important because it demonstrates that there may be safe ways to increase drug delivery to the brain without any serious adverse effects.”
More than 98% of drugs are blocked by the barrier, which means patients require higher doses and more frequent therapies, the researchers noted.
ALZHEIMER’S BLOOD TEST COULD HIT THE MARKET IN EARLY 2024, RESEARCHERS SAY
In this study, scientists used a focused ultrasound (FUS) system to temporarily open the blood-brain barrier, which allowed the antibodies to have greater access to areas of the brain with high amyloid-beta plaques.
After six months of antibody treatment, the study participants had an average of 32% more reduction in amyloid-beta plaques in areas where the BBB was opened compared to areas where the drug was used without the ultrasound, the release stated.
The WVU RNI team, shown in the MRI suite’s control area, plans ultrasound blood-brain barrier treatment. (Rockefeller Neuroscience Institute (RNI) at West Virginia University (WVU))
“This was a first in human safety and feasibility study in three participants demonstrating that the BBB opening can accelerate clearance of beta amyloid plaques,” study lead Dr. Ali Rezai, director of the Rockefeller Neuroscience Institute (RNI) at WVU, told Fox News Digital.
“Non-invasive focused ultrasound is an outpatient procedure that allows for targeted delivery of therapeutics to the brain that can potentially accelerate the benefit of the antibody treatment in Alzheimer’s disease,” he added.
DEMENTIA AMONG YOUNGER PEOPLE IS LINKED TO 15 FACTORS, MAJOR STUDY REVEALS
The three patients, between the ages of 59 and 77, all had mild Alzheimer’s disease.
During the study, they received six monthly infusions of the aducanumab antibody.
After each treatment, the focused ultrasound was used to open the BBB at the sites of the highest plaque buildup.
While there are some potential risks associated with ultrasound use, such as brain swelling and hemorrhage, Rezai said those effects were not observed in this study.
The focused ultrasound helmet unit with 1,024 ultrasound transducers attaches to the MRI table for MRI-guided treatment. (Rockefeller Neuroscience Institute (RNI) at West Virginia University (WVU))
“We verified with MRI scans that the BBB opening was temporary and it closed 24 to 48 hours after the FUS procedure,” he told Fox News Digital.
The reductions in amyloid plaques were verified in PET scans.
SMOKING SHRINKS THE BRAIN AND DRIVES UP ALZHEIMER’S RISK, NEW STUDY FINDS
This was the first step toward larger studies; in those, researchers will be able to evaluate more patients and larger areas of the brain, Rezai noted.
In the next phase of the clinical trial, the ultrasound therapy will be paired with lecanemab, another anti-beta amyloid antibody.
This 3-D illustration shows how ultrasound waves from inside the helmet converge on a focal point on the brain used for blood-brain barrier opening. (Rockefeller Neuroscience Institute (RNI) at West Virginia University (WVU))
Dr. James Galvin, director of the Comprehensive Center for Brain Health at UHealth, the University of Miami Health System, was not involved in the WVU research but shared his reaction.
“A study like this is important because it demonstrates that there may be safe ways to increase drug delivery to the brain without any serious adverse effects,” he told Fox News Digital.
DEMENTIA’S STAGGERING FINANCIAL COST IS REVEALED IN NEW REPORT: IT’S ‘BANKRUPTING FAMILIES’
“Focused ultrasound has been used in other treatment paradigms for brain diseases such as Parkinson’s disease and brain tumors,” Galvin went on.
Galvin also cautioned that this research was conducted with only three patients and was not a placebo-controlled study.
As of 2023, an estimated 6.7 million Americans age 65 and older were living with Alzheimer’s. (iStock)
“It was also designed as a safety study and not appropriately powered to detect significant clinical changes,” he added. “It is still too early to make any specific recommendations, but I am excited to see if there are planned follow-up studies with a larger number of patients.”
Rebecca M. Edelmayer, PhD, senior director of scientific engagement at the Alzheimer’s Association, was also not involved in the study but called the results “very intriguing,” albeit preliminary.
“The blood brain barrier, in its healthy form, protects the brain from harmful agents that could reach it via the bloodstream,” she told Fox News Digital via email.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Getting therapeutics across this barrier — from the bloodstream into the brain tissue — is a challenge for any drug used to treat brain diseases, including drugs to treat Alzheimer’s disease.”
Edelmayer added that while this was a “very small study of relatively short length,” it was a worthwhile way to test a “cutting-edge idea” for improving the effectiveness of Alzheimer’s medications.
This illustration of the MRI-guided focused ultrasound system includes a representation of treatment delivery, the target region, and the corresponding opening of the blood-brain barrier demonstrated by contrast enhancement. (Rockefeller Neuroscience Institute (RNI) at West Virginia University (WVU))
Focused ultrasound-induced blood-brain barrier opening has also been shown to improve drug delivery to treat brain tumors, Edelmayer pointed out.
“This is a great example of how learnings from research in other diseases might be repurposed for Alzheimer’s disease and other dementia.”
Looking ahead, Edelmayer said the results of this early research point to the need for larger-scale, longer trials.
“We need more research in individuals with Alzheimer’s disease from all communities to know the full impact this approach could have.”
For more Health articles, visit www.foxnews.com/health.
Health
Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
Lurking dementia risk exposed by breakthrough test 25 years before symptoms
Study finds link between obesity and vascular dementia
Fox News senior medical analyst Dr. Marc Siegel joins ‘America’s Newsroom’ to discuss an increase in colon cancer in people under 50 despite an overall lowering cancer deaths and a new study linking obesity to vascular dementia.
NEWYou can now listen to Fox News articles!
A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.
That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.
The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release.
KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS
The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.
After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia.
A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge. (iStock)
Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.
“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital.
“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”
“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.
This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.
A specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk. (iStock)
“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.
This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.
The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release.
“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” a researcher said. (iStock)
“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”
Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
More research is needed before this approach can be considered for clinical use prior to cognitive symptoms.
Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.
CLICK HERE FOR MORE HEALTH STORIES
“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”
Health
Key fitness measure is strong predictor of longevity after certain age, study finds
NEWYou can now listen to Fox News articles!
For women over 60, muscle strength plays a critical role in longevity, a new study confirms.
Researchers at the University at Buffalo, New York, followed more than 5,000 women between the ages of 63 and 99, finding that those with greater muscle strength had a significantly lower risk of death over an eight-year period.
The findings were published in JAMA Network Open.
EXERCISE AFFECTS THE HEART IN A HIDDEN, POWERFUL WAY BY REWIRING NERVES, STUDY FINDS
Muscle function was measured using grip strength and how quickly participants could complete five unassisted sit-to-stand chair raises.
These are two tests commonly used in clinical settings to evaluate muscle function in older adults, the researchers noted.
A recent study shows that stronger muscle strength in women over 60 is linked to a lower risk of death over eight years. (iStock)
“In a community cohort of ambulatory older women, muscular strength was associated with significantly lower mortality rates, even when we accounted for usual physical activity and sedentary time measured using a wearable monitor, gait speed and blood C-reactive protein levels,” study lead author Michael LaMonte, research professor of epidemiology and environmental health at the University at Buffalo, told Fox News Digital.
“Movement is the key — just move more and sit less.”
Many earlier studies did not include those objective measurements, making it difficult to determine whether muscle strength itself was linked to longevity, according to LaMonte. “Our study was able to better isolate the association between strength and death in later life,” he added.
Even for women who don’t get the recommended amount of aerobic physical activity, which is at least 150 minutes per week, muscle strength remained important for longevity, the researchers found.
Women with greater muscle strength were more likely to live longer, even if they did not meet the recommended amount of aerobic exercise. (iStock)
“The findings of lower mortality in those who had higher strength but were not meeting current national guidelines on aerobic activity were somewhat intriguing,” LaMonte said.
CLICK HERE FOR MORE LIFESTYLE STORIES
Federal guidelines recommend strengthening activities one to two days per week, targeting major muscle groups.
Resistance training does not have to require a gym membership, LaMonte noted. These exercises can be performed using free weights, resistance bands, bodyweight movements or even household items, such as soup cans.
Experts recommend working major muscle groups one or two days a week using weights, bands or bodyweight exercises. (iStock)
“Movement is the key — just move more and sit less,” he said. “When we can no longer get out of the chair and move around, we are in trouble.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
LaMonte acknowledged several limitations of the study. The researchers assessed muscle strength in older age but did not explore how earlier levels in adulthood might influence long-term health outcomes.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“We were not able to understand how strength and mortality relate in younger ages,” he said, noting that future research should explore whether building strength earlier could have an even greater impact on longevity.
-
Wisconsin1 week agoSetting sail on iceboats across a frozen lake in Wisconsin
-
Massachusetts1 week agoMassachusetts man awaits word from family in Iran after attacks
-
Pennsylvania6 days agoPa. man found guilty of raping teen girl who he took to Mexico
-
Detroit, MI5 days agoU.S. Postal Service could run out of money within a year
-
Miami, FL7 days agoCity of Miami celebrates reopening of Flagler Street as part of beautification project
-
Sports6 days agoKeith Olbermann under fire for calling Lou Holtz a ‘scumbag’ after legendary coach’s death
-
Virginia7 days agoGiants will hold 2026 training camp in West Virginia
-
Culture1 week agoTry This Quiz on the Real Locations in These Magical and Mysterious Novels